Efforts have been made to select appropriate candidates for TACE and RFA treatment based on the Barcelona Clinic Liver Cancer (BCLC) staging system and on histopathologic grade, AFP and performance status as well as vascular invasion (Makary et al., 2020). The gene discussed is AFP; the disease is liver cancer.